TriSalus Life Sciences to Host Third Quarter 2023 Financial Results Conference Call
08 November 2023 - 8:05AM
Business Wire
– Call Scheduled for Tuesday, November 14,
2023, at 9:00 a.m. ET –
TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology
company integrating its novel delivery technology with
immunotherapy to transform treatment for patients with liver and
pancreatic tumors, today announced it will host a conference call
and webcast on November 14, 2023, at 9:00 a.m. ET to discuss
financial results for the third quarter ended September 30, 2023,
and provide a business update. A press release detailing third
quarter results will be issued prior to the call.
The event will be webcast live on the investor relations section
of TriSalus’ website at
https://investors.trisaluslifesci.com/news-events/events-presentations.
Following the conclusion of the event, a webcast replay will be
available on the website for approximately 90 days. Interested
parties participating by phone will need to register using this
online form. After registering for the webcast, dial-in details
will be provided in an auto-generated e-mail containing a link to
the conference phone number along with a personal pin.
About TriSalus Life Sciences
TriSalus Life Sciences is an oncology company integrating novel
delivery technology with immunotherapy to transform treatment for
patients with liver and pancreatic tumors.
The Company’s platform includes devices that utilize a
proprietary drug delivery technology and a clinical-stage
investigational immunotherapy. The Company’s two FDA-cleared
devices use its proprietary Pressure-Enabled Drug Delivery™ (PEDD™)
approach to deliver a range of therapeutics: the TriNav® Infusion
System for hepatic arterial infusion of liver tumors and the
Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
PEDD is a novel delivery approach designed to address the anatomic
limitations of arterial infusion to the pancreas. The PEDD approach
modulates pressure and flow in a manner that delivers more
therapeutic to the tumor and is designed to reduce undesired
delivery to normal tissue, bringing the potential to improve
patient outcomes. SD-101, the Company’s investigational
immunotherapeutic candidate, is designed to improve patient
outcomes by treating the immunosuppressive environment created by
many tumors, which can make current immunotherapies ineffective in
the liver and pancreas. Patient data generated during
Pressure-Enabled Regional Immuno-Oncology™ (PERIO) clinical trials
support the hypothesis that SD-101 delivered via PEDD may have
favorable immune effects within the liver and systemically. The
target for SD-101, TLR9, is expressed across cancer types and the
mechanical barriers addressed by PEDD are commonly present as well.
SD-101 delivered by PEDD will be studied across several indications
in an effort to address immune dysfunction and overcome drug
delivery barriers in the liver and pancreas.
In partnership with leading cancer centers across the country –
and by leveraging deep immuno-oncology expertise and inventive
technology development – TriSalus is committed to advancing
innovation that improves outcomes for patients. Learn more at
trisaluslifesci.com and follow us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107566805/en/
For Media and Investor Inquiries: Argot Partners
212.600.1902 TriSalus@argotpartners.com
TriSalus Life Sciences (NASDAQ:TLSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
TriSalus Life Sciences (NASDAQ:TLSI)
Historical Stock Chart
From Sep 2023 to Sep 2024